In observation of Rare Disease Day, the House Energy and Commerce Health Subcommittee is scheduled to hold a hearing today to discuss important bills impacting the rare disease community. During this hearing, several pieces of legislation will be addressed, including the Inflation Reduction Act, the ORPHAN Cures Act, and the MINI Act.
Read MoreIn a newly published document, “What They Are Saying About the Biden Administration’s Draft Framework for March-In Rights,” Conservatives for Property Rights has compiled comments on the Biden administration’s proposal to assert march-in authority under the Bayh-Dole Act.
Read MoreTAPP sent a thank-you note to members of Congress who signed onto a letter to the Biden Administration opposing recently released NIST guidance that would facilitate the misapplication of march-in authority under the Bayh-Dole Act.
Read MoreRecently, TAPP responded to a National Institute of Standards and Technology (NIST) request for information regarding the draft interagency guidance framework for considering the exercise of march-in rights. Today, TAPP aided Senator Coons (D-DE), Senator Tillis (R-NC), and Rep. Auchincloss (D-MA) in circulating a bipartisan letter to the House and Senate opposing the NIST guidance.
Read MoreTAPP recently responded to a National Institute of Standards and Technology request for information regarding the draft interagency guidance framework for considering the exercise of march-in rights. In its letter to NIST, TAPP urged rejection of any attempt to assert march-in authority as it would constitute a misapplication of the four-decades-old Bayh-Dole Act and would harm healthcare innovators and patients.
Read MoreThe Trade Alliance to Promote Prosperity wrote to the U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP) following Bernie Sanders's decision to subpoena two drug company CEOs. At the hearing, we expect Sanders and his allies in Congress to push for the adoption of drug policies such as the Most Favored Nation model (MFN) and an international pricing index (IPI). As we have said before, such proposals would simply import foreign price controls into America’s healthcare system, harming innovation and the development of new medicines.
Read MoreOn Thursday, January 18, the Department of Homeland Security executed a search warrant at the Ohio-based U.S. subsidiary of Qingdao Sunsong, a Chinese automobile parts manufacturer. This comes eight months after the Trade Alliance to Promote Prosperity (TAPP) launched its “Tariff Integrity” initiative, drawing attention to the Sunsong case.
Read MoreTrade Alliance to Promote Prosperity Executive Director Kent Kaiser, Ph.D., penned an op-ed that appeared recently in the DC Journal, an Inside Sources publication. From now through February 6, the Biden administration is seeking public comments that could be considered in deciding whether to misapply the Bayh-Dole Act in a way that the law's author's never intended and in a way that would ultimately harm American patients and innovators. TAPP is calling on Americans to tell the president to reverse course.
Read MorePresident Biden is moving to impose “march-in” rights on prescription drugs with the stated goal of lowering prices. The idea sounds good at first blush, but it actually will be devastating to patients across the country and to America’s global preeminence in medical innovation.
Read MoreThe Trade Alliance to Promote Prosperity has joined over 80 other organizations in signing onto a letter to congressional leaders pushing back against drug price-setting provisions contained in the deceptively named Inflation Reduction Act.
Read MoreThe Trade Alliance to Promote Prosperity applauds the unanimous December 6 passage of the bipartisan Senate Resolution 445 sponsored by U.S. Senators Marsha Blackburn (R-Tennessee) and Catherine Cortez Masto (D-Nevada). The resolution calls for strengthening economic ties between the U.S. and Israel amid Israel’s war against Hamas in response to the terrorist group’s gruesome assault on Israel on October 7, which has stunted Israel’s economy.
Read MoreTrade Alliance to Promote Prosperity Executive Director Kent Kaiser, Ph.D., penned an op-ed that appeared recently in the DC Journal, an Inside Sources publication.
Read MoreTAPP is once again sounding the alarm on the possible misuse of the Bayh-Dole Act by the Biden Administration to impose price controls. A U.S. Department of Health and Human Services (HHS) and Department of Commerce (DOC) working group is expected to release recommendations on the implementation of the Bayh-Dole Act’s “march-in” provision soon.
Read MoreAs TAPP has said, the Inflation Reduction Act is a threat to the American pharmaceutical industry and patients everywhere. A recent article from The Wall Street Journal highlights the damage done to an American biotech company, Seagan Inc., as it was forced to shut down a successful cancer treatment because of this legislation.
Read MoreOn October 31, the U.S. Government Accountability Office released a report, “Sugar Program: Alternative Methods for Implementing Import Restrictions Could Increase Effectiveness.”
Read MoreThe Trade Alliance to Promote Prosperity joined more than 40 organizations in writing to Congress and urging the members to repeal the prescription drug price controls in the IRA.
Read MoreThe Trade Alliance to Promote Prosperity today wrote to U.S. Senator Marsha Blackburn to thank her for her planned resolution recognizing the importance of the U.S.-Israel Free Trade Agreement.
Read MoreThe Trade Alliance to Promote Prosperity wrote to the U.S. Senate Committee on Health, Education, Labor, and Pensions in advance of a full committee meeting to consider the nomination of Monica Bertagnolli to lead the National Institutes of Health, urging the committee to reject anti-competitive and anti-innovation schemes that might arise during the discussions…
Read MoreLast week, a number of judges, former government officials, and scholars who are experts in patent law, healthcare policy, or both, wrote a letter to U.S. legislators in an effort to stop the government from imposing price controls on patented drugs.
Read MoreTAPP and 11 other organizations recently signed a letter challenging the Biden Administration on its mismanagement of the No Surprises Act.
Read More